Enveric Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Enveric Biosciences
ENVB Stock  USD 0.44  0.04  8.33%   
Enveric Biosciences financial statements provide useful quarterly and yearly information to potential Enveric Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Enveric Biosciences financial statements helps investors assess Enveric Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Enveric Biosciences' valuation are summarized below:
Gross Profit
8.2 M
Market Capitalization
4.3 M
Enterprise Value Revenue
1.7579
Revenue
35.4 M
Earnings Share
(3.98)
We have found one hundred twenty available fundamental signals for Enveric Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Enveric Biosciences prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of October 17, 2024, Market Cap is expected to decline to 2,640. The current year's Enterprise Value is expected to grow to about (2.2 M)

Enveric Biosciences Total Revenue

0.0

Check Enveric Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enveric Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 327, Interest Expense of 3.5 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.33, Dividend Yield of 475.8 K or PTB Ratio of 7.0E-4. Enveric financial statements analysis is a perfect complement when working with Enveric Biosciences Valuation or Volatility modules.
  
Check out the analysis of Enveric Biosciences Correlation against competitors.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

Enveric Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9 M6.1 M15.2 M
Slightly volatile
Other Current Liabilities1.9 M1.1 M3.2 M
Pretty Stable
Total Current Liabilities3.7 M2.3 M6.3 M
Pretty Stable
Property Plant And Equipment Net532.7 K507.4 K215.9 K
Slightly volatile
Accounts Payable1.3 M1.2 M2.6 M
Pretty Stable
Cash2.3 M2.3 M3.5 M
Slightly volatile
Non Current Assets Total2.9 M3.1 M10.4 M
Very volatile
Cash And Short Term Investments2.4 M2.3 M3.5 M
Slightly volatile
Net Receivables245.4 K258.3 K4.2 M
Slightly volatile
Common Stock Shares Outstanding2.1 K2.2 K138.5 K
Slightly volatile
Liabilities And Stockholders Equity9 M6.1 M15.2 M
Slightly volatile
Other Current Assets279.7 K501.3 K429.3 K
Slightly volatile
Other Stockholder Equity105.9 M100.8 M49.5 M
Slightly volatile
Total Liabilities2.2 M2.3 M8.1 M
Very volatile
Total Current Assets4.2 M3 M6.5 M
Slightly volatile
Intangible Assets200.4 K210.9 K3.5 M
Pretty Stable
Short and Long Term Debt Total69.7 K73.4 K2.7 M
Very volatile
Short Term Debt69.7 K73.4 K1.7 M
Pretty Stable
Common Stock26 K27.4 K139.9 K
Pretty Stable
Common Stock Total Equity21.6 K22.7 K133.3 K
Slightly volatile
Property Plant And Equipment Gross908.3 K865.1 K269.9 K
Slightly volatile
Short Term Investments70.9 K74.6 K142.7 K
Slightly volatile
Long Term Debt1.9 M2.1 M2.3 M
Slightly volatile
Net Invested Capital1.9 M2 M19.2 M
Slightly volatile
Short and Long Term Debt5.5 M5.6 M4.9 M
Slightly volatile
Capital Stock26 K27.4 K294 K
Slightly volatile
Other Liabilities1.8 M2 M2.2 M
Slightly volatile
Property Plant Equipment376.6 K423.7 K461.3 K
Slightly volatile
Other Assets0.80.90.98
Slightly volatile

Enveric Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses15.6 K16.4 K17.5 M
Pretty Stable
Cost Of Revenue387.6 K408 K11.1 M
Very volatile
Total Operating Expenses15.6 K16.4 K7.9 M
Slightly volatile
Research Development6.9 K7.3 K1.1 M
Pretty Stable
Selling General Administrative8.4 K8.9 K5.5 M
Slightly volatile
Selling And Marketing Expenses1251312.5 M
Very volatile
Reconciled Depreciation393.3 K414 K2.2 M
Slightly volatile
Interest Income3 K3.3 K3.6 K
Slightly volatile

Enveric Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow18.6 M17.7 M4.5 M
Slightly volatile
End Period Cash Flow2.3 M2.3 M3.5 M
Slightly volatile
Stock Based Compensation4.1 M2.2 M2.8 M
Slightly volatile
Net Borrowings2 M1.9 M970.1 K
Slightly volatile
Dividends Paid2.5 T2.4 T1 T
Slightly volatile
Change To Netincome43.1 M41 M10.9 M
Slightly volatile
Change To Liabilities395.6 K440.7 K236.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.330.341.9 K
Slightly volatile
Dividend Yield475.8 K453.2 K229.8 K
Slightly volatile
Days Sales Outstanding10767.1490.7725
Slightly volatile
Average Payables818.9 K614.1 K2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.01610.01690.0366
Slightly volatile
Capex To Depreciation0.01210.01274.0898
Slightly volatile
EV To Sales0.450.471.9 K
Slightly volatile
Payables Turnover0.320.33483.2045
Slightly volatile
Sales General And Administrative To Revenue1.0E-41.0E-40.1771
Slightly volatile
Average Inventory7.1 K7.5 K26.1 K
Slightly volatile
Research And Ddevelopement To Revenue0.560.540.5357
Slightly volatile
Capex To Revenue0.00230.00240.0763
Slightly volatile
Cash Per Share5831.1 K412
Very volatile
Days Payables Outstanding1.2 K1.1 K438
Slightly volatile
Income Quality0.770.81429.684
Pretty Stable
Intangibles To Total Assets0.03280.03450.392
Slightly volatile
Current Ratio1.221.28611.7615
Slightly volatile
Receivables Turnover3.825.634.5844
Slightly volatile
Graham Number5385673.6 K
Very volatile
Capex Per Share2.32.4228337
Slightly volatile
Average Receivables96 K101.1 K4.6 M
Slightly volatile
Revenue Per Share2.6 K1.4 K5.5 K
Slightly volatile
Debt To Assets0.00360.00380.3266
Slightly volatile
Days Of Payables Outstanding1.2 K1.1 K438
Slightly volatile
Long Term Debt To Capitalization0.00340.00350.3381
Slightly volatile
Quick Ratio1.221.28611.7482
Slightly volatile
Cash Ratio0.930.97631.3834
Slightly volatile
Days Of Sales Outstanding10767.1490.7725
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.851.00041.2551
Slightly volatile
Fixed Asset Turnover454432367
Slightly volatile
Debt Ratio0.00360.00380.3266
Slightly volatile
Price Sales Ratio0.330.341.9 K
Slightly volatile
Asset Turnover0.741.441.1815
Slightly volatile
Gross Profit Margin0.220.230.305
Slightly volatile
Operating Cycle63.7867.14124
Slightly volatile

Enveric Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.6 K2.8 K382 M
Slightly volatile

Enveric Fundamental Market Drivers

Forward Price Earnings23.0947
Cash And Short Term Investments2.3 M

Enveric Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Enveric Biosciences Financial Statements

Enveric Biosciences stakeholders use historical fundamental indicators, such as Enveric Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Enveric Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Enveric Biosciences' assets and liabilities are reflected in the revenues and expenses on Enveric Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Enveric Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.2 M
Cost Of Revenue408 K387.6 K
Stock Based Compensation To Revenue 0.02  0.02 
Research And Ddevelopement To Revenue 0.54  0.56 
Revenue Per Share1.4 K2.6 K
Ebit Per Revenue(0.14)(0.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
AVAVAeroVironment
ELVNEnliven Therapeutics
NFLXNetflix
When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:
How To Invest In Enveric
Details
Is Enveric Stock a good investment?
Details
What is Enveric Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Enveric Biosciences Correlation against competitors.
For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.98)
Revenue Per Share
37.678
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.81)
Return On Equity
(2.06)
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY